Drug Database
Back to search

Netherlands· NL-7c07bd8f46dd

Breyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectie

A lisocabtagene maraleucel product containing lisocabtageen maraleucel (cd4+ component), registered in Netherlands by Celgene Europe B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC L01XL08

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBreyanzi >= 5.1 x 10^6 cellen [CD4 co…ATCL01XL08REGISTER NO.NL-7c07bd8f46ddPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lisocabtageen maraleucel (cd4+ component)Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lisocabtagene maraleucel is registered in 12 of 19 countries.

Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search lisocabtagene maraleucel products by name

Lisocabtagene maraleucel · ATC L01XL08

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LISOCABTAGEEN MARALEUCEL (CD4+ component)
Manufacturer
Celgene Europe B.V.
Country
Netherlands (NL)
ATC code
L01XL08
ATC class
Lisocabtagene maraleucel
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1631

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

37 interactions on record for lisocabtagene maraleucel.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lisocabtagene maraleucel against other medicinesHow interaction checks work

Lisocabtagene maraleucel · interactions on record

37 records

  • 21 severe
  • 16 moderate

Most severe, free to view

  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • NatalizumabL04AA23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lisocabtagene maraleucel in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lisocabtagene maraleucel products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Breyanzi
  • Liechtenstein · Breyanzi
  • Norway · Breyanzi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e824d021-93d7-4979-b68f-4f7a73815d8e
GET /v1/drugs/e824d021-93d7-4979-b68f-4f7a73815d8e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspensie voor injectie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/breyanzi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lisocabtagene Maraleucel",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126986",
  "excipients": [
    "ADENOSINE",
    "CALCIUMCHLORIDE 2-WATER (E 509)",
    "CAPRYLZUUR (E 570)",
    "DEXTRAAN 40",
    "DIMETHYLSULFOXIDE",
    "GLUCOSE 0-WATER",
    "GLUTATHION (L-)",
    "HUMAAN ALBUMINE",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "KALIUMHYDROXIDE (E 525)",
    "KALIUMWATERSTOFCARBONAAT (E 501 (II))",
    "LACTOBIONZUUR",
    "MAGNESIUMCHLORIDE 6-WATER (E 511)",
    "MANNITOL (D-) (E 421)",
    "N-2-HYDROXYETHYLPIPERAZINE-N'-2-ETHAANSULFONZUUR",
    "N-ACETYL-D,L-TRYPTOFAAN",
    "NATRIUMACETAAT 3-WATER (E 262)",
    "NATRIUMCHLORIDE",
    "NATRIUMGLUCONAAT (E 576)",
    "NATRIUMHYDROXIDE (E 524)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "LISOCABTAGEEN MARALEUCEL (CD4+ component)"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/04/04",
  "procedure_number": "EMEA/H/C/004731",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1631",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about lisocabtagene maraleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console